- Home
- SPRO vs CNTY Comparison
SPRO vs CNTY Comparison
Compare SPRO & CNTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- CNTY
- Stock Information
- Founded
- SPRO 2013
- CNTY 1992
- Country
- SPRO United States
- CNTY United States
- Employees
- SPRO N/A
- CNTY N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- CNTY Hotels/Resorts
- Sector
- SPRO Health Care
- CNTY Consumer Discretionary
- Exchange
- SPRO Nasdaq
- CNTY Nasdaq
- Market Cap
- SPRO 63.0M
- CNTY 120.3M
- IPO Year
- SPRO 2017
- CNTY 1993
- Fundamental
- Price
- SPRO $0.97
- CNTY $2.91
- Analyst Decision
- SPRO Buy
- CNTY Strong Buy
- Analyst Count
- SPRO 4
- CNTY 4
- Target Price
- SPRO $5.00
- CNTY $5.50
- AVG Volume (30 Days)
- SPRO 247.7K
- CNTY 79.4K
- Earning Date
- SPRO 11-14-2024
- CNTY 03-13-2025
- Dividend Yield
- SPRO N/A
- CNTY N/A
- EPS Growth
- SPRO N/A
- CNTY N/A
- EPS
- SPRO 0.06
- CNTY N/A
- Revenue
- SPRO $106,455,000.00
- CNTY $581,905,000.00
- Revenue This Year
- SPRO N/A
- CNTY $8.07
- Revenue Next Year
- SPRO N/A
- CNTY $9.46
- P/E Ratio
- SPRO $15.29
- CNTY N/A
- Revenue Growth
- SPRO 37.01
- CNTY 14.05
- 52 Week Low
- SPRO $0.92
- CNTY $1.94
- 52 Week High
- SPRO $1.89
- CNTY $5.09
- Technical
- Relative Strength Index (RSI)
- SPRO 39.40
- CNTY 33.37
- Support Level
- SPRO $0.92
- CNTY $2.81
- Resistance Level
- SPRO $1.13
- CNTY $3.01
- Average True Range (ATR)
- SPRO 0.06
- CNTY 0.21
- MACD
- SPRO 0.00
- CNTY -0.02
- Stochastic Oscillator
- SPRO 26.16
- CNTY 18.52
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurant, horse racing (including off-track betting), and entertainment facilities in North America. The company has three reportable segments based on the geographical locations in which its casinos operate; United States; Century Casino & Hotel-Central City, and Century Casino & Hotel-Cripple Creek in Colorado, Mountaineer Casino, Racetrack & Resort in West Virginia, and Century Casino Caruthersville, and Century Casino Cape Girardeau in Missouri, Canada; Century Casino & Hotel, Century Casino St. Albert, Century Mile Racetrack in Edmonton and Casino Century Downs Racetrack and Casino in Calgary, and Poland; Casinos Poland.